| Literature DB >> 34675555 |
Reem Al Dossary1, Amani Alnimr1, Reem Aljindan1, Khaled R Alkharsah1, Ahmed K Al-Qurayn1, Obeid Eltreifi1, Feras A Alkuwaiti2, Abdullah B Almashouf2, Ahmed M Alsahlawi2, Amal Alshammari3, Dhoha Hudhaiah3, Mohammed S Alshahrani4, Huda Bukhari2.
Abstract
PURPOSE: Multiple studies worldwide have reported the clinical and epidemiological features of coronavirus disease 2019 (COVID-19), with limited reports from the Middle East. This study describes the clinical and epidemiological features of COVID-19 cases in the Eastern Province of Saudi Arabia and identified factors associated with the severity of illness. PATIENTS AND METHODS: This was an observational study of 341 COVID-19 cases. These cases were reported in the first three months after the first case in the country was identified. Clinical and demographic data were analyzed and described to identify the effects of age, sex, and ethnicity on illness severity. In addition, the duration of viral shedding and cycle threshold (Ct) values of real-time PCR were evaluated as predictors of severity.Entities:
Keywords: Arabs; Ct value; ethnicity; factors; virus shedding
Year: 2021 PMID: 34675555 PMCID: PMC8502032 DOI: 10.2147/IDR.S333300
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
Multivariate Analysis of the Age Groups and Disease Severity with Other Demographic and Clinical Variables
| Value | F | Hypothesis Degrees of Freedom | Error Degrees of Freedom | Significance | Partial Eta Squared | Observed Power | |
|---|---|---|---|---|---|---|---|
| Age groups | 0.262 | 1.752 | 54.000 | 987.000 | 0.001 | 0.087 | 1.000 |
| Disease severity | 0.413 | 3.257 | 42.000 | 858.000 | 0.000 | 0.138 | 1.000 |
Figure 1The spectrum of the severity of illness among the 341 COVID-19 cases.
Clinical Features of COVID-19 Cases Between March and June 2020 According to Age Groups
| Clinical Features | Infant (≤1 Year) | Children (>1–19 Years) | Adults (>19–65) | Senior Adults (65+) | Total | P- value* | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| N=5 | % | N=18 | % | N=280 | % | N= 38 | % | N= 341 | ||
| Fever | 5 | 2.16 | 12 | 5.19 | 189 | 81.82 | 25 | 10.82 | 231 | 0.296 |
| Shivering | 0 | 0.00 | 0 | 0.00 | 22 | 95.65 | 1 | 4.35 | 23 | 0.936 |
| Shortness of Breath | 2 | 1.31 | 4 | 2.61 | 127 | 83.01 | 20 | 13.07 | 153 | 0.106 |
| Chest pain | 0 | 0.00 | 1 | 7.14 | 12 | 85.71 | 1 | 7.14 | 14 | 0.598 |
| Wheezes | 0 | 0.00 | 0 | 0.00 | 3 | 75.00 | 1 | 25.00 | 4 | 0.683 |
| Cough | 1 | 0.53 | 6 | 3.19 | 158 | 84.04 | 23 | 12.23 | 188 | 0.038 |
| Sputum production | 0 | 0.00 | 0 | 0.00 | 17 | 80.95 | 4 | 19.05 | 21 | 0.179 |
| Hemoptysis | 0 | 0.00 | 1 | 25.0 | 2 | 50.00 | 1 | 25.00 | 4 | 0.511 |
| Rhinorrhea | 0 | 0.00 | 3 | 30.0 | 6 | 60.00 | 1 | 10.00 | 10 | 0.057 |
| Loss of taste/smell | 0 | 0.00 | 0 | 0.00 | 3 | 100.00 | 0 | 0.00 | 3 | 0.470 |
| Sore Throat | 0 | 0.00 | 3 | 9.68 | 26 | 83.87 | 2 | 6.45 | 31 | 0.336 |
| Headache | 0 | 0.00 | 3 | 10.00 | 24 | 80.00 | 3 | 10.00 | 30 | 0.576 |
| Myalgia | 0 | 0.00 | 3 | 5.56 | 41 | 75.93 | 10 | 18.52 | 54 | 0.122 |
| Vomiting | 0 | 0.00 | 4 | 11.76 | 30 | 88.24 | 0 | 0.00 | 34 | 0.035 |
| Diarrhea | 1 | 2.63 | 1 | 2.63 | 32 | 84.21 | 4 | 10.53 | 38 | 0.823 |
| Abdominal pain | 0 | 0.00 | 1 | 14.29 | 6 | 85.71 | 0 | 0.00 | 7 | 0.168 |
| Nausea | 0 | 0.00 | 0 | 0.00 | 7 | 77.78 | 2 | 22.22 | 9 | 0.376 |
| Anorexia | 0 | 0.00 | 0 | 0.00 | 1 | 16.67 | 5 | 83.33 | 6 | <0.001 |
Note: *Significance is defined as p<0.05.
The Distribution of COVID-19 Cases Based on Gender, Age, Co-Morbidities, and Nationality Relative to the Disease Severity
| Variables | Asymptomatic | Mild to Moderate | Severe | Critical | Total | p-value* | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| N 52 | % | N 153 | % | N 74 | % | N 62 | % | |||
| Female | 22 | 19.30 | 60 | 52.63 | 22 | 19.30 | 10 | 8.77 | 114 | <0.001 |
| Male | 29 | 12.83 | 93 | 41.15 | 52 | 23.01 | 52 | 23.01 | 226 | |
| Infant (=<1year) | 2 | 40.00 | 2 | 40.00 | 1 | 20.00 | 0 | 0.00 | 5 | 0.08 |
| Children (>1–19 years) | 4 | 21.05 | 12 | 63.16 | 3 | 15.79 | 0 | 0.00 | 19 | 0.017 |
| Adults (>19–65) | 43 | 15.36 | 128 | 45.71 | 59 | 21.07 | 50 | 17.86 | 280 | 0.52 |
| Senior adults (>65) | 3 | 8.11 | 11 | 29.73 | 11 | 29.73 | 12 | 32.43 | 37 | 0.004 |
| Diabetes Mellitus | 4 | 4.04 | 26 | 26.26 | 32 | 32.32 | 37 | 37.37 | 99 | <0.001 |
| Hypertension | 5 | 6.17 | 23 | 28.40 | 32 | 39.51 | 21 | 25.93 | 81 | <0.001 |
| Smoking | 0 | 0.00 | 1 | 20.00 | 3 | 60.00 | 1 | 20.00 | 5 | 0.23 |
| Heart Failure | 1 | 12.50 | 2 | 25.00 | 5 | 62.50 | 0 | 0.00 | 8 | 0.96 |
| Cancer | 1 | 16.67 | 3 | 50.00 | 0 | 0.00 | 2 | 33.33 | 6 | 0.97 |
| Dyslipidemia | 1 | 3.23 | 8 | 25.81 | 12 | 38.71 | 10 | 32.26 | 31 | <0.001 |
| CAD | 1 | 14.29 | 4 | 57.14 | 1 | 14.29 | 1 | 14.29 | 7 | 0.55 |
| CKD | 5 | 14.71 | 8 | 23.53 | 8 | 23.53 | 12 | 35.29 | 34 | 0.23 |
| Bronchial Asthma | 0 | 0.00 | 4 | 57.14 | 3 | 42.86 | 0 | 0.00 | 7 | 0.84 |
| SCD | 0 | 0.00 | 4 | 80.00 | 1 | 20.00 | 0 | 0.00 | 5 | 0.44 |
| Saudi | 37 | 19.9 | 93 | 50.0 | 36 | 19.4 | 20 | 10.8 | 186 | <0.001 |
| Bahraini | 0 | 0.0 | 0 | 0.0 | 1 | 100.0 | 0 | 0.0 | 1 | – |
| Egyptian | 7 | 43.8 | 4 | 25.0 | 4 | 25.0 | 1 | 6.3 | 16 | 0.025 |
| Jordanian | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 2 | 100.0 | 2 | 0.05 |
| Yemeni | 1 | 11.1 | 4 | 44.4 | 1 | 11.1 | 3 | 33.3 | 9 | 0.56 |
| Bengali | 2 | 5.1 | 8 | 20.5 | 12 | 30.8 | 17 | 43.6 | 39 | <0.001 |
| Indian | 1 | 2.5 | 23 | 57.5 | 7 | 17.5 | 9 | 22.5 | 40 | 0.26 |
| Pakistani | 0 | 0.0 | 10 | 52.6 | 4 | 21.1 | 5 | 26.3 | 19 | 0.18 |
| Philippine | 3 | 13.6 | 8 | 36.4 | 8 | 36.4 | 3 | 13.6 | 22 | 0.8 |
| Somalian | 0 | 0.0 | 1 | 100.0 | 0 | 0.0 | 0 | 0.0 | 1 | – |
| Sudanese | 1 | 20.0 | 1 | 20.0 | 1 | 20.0 | 2 | 40.0 | 5 | 0.52 |
Note: *Significance is defined as p<0.05.
Abbreviation: SCD, sickle cell disease.
Figure 2Dynamics of SARS-CoV2 viral clearance of 135 cases based on SARS-CoV-2 RNA detection.
Figure 3Frequency of cycle threshold (Ct) values for the E and N2 gene targets relative to COVID-19 severity (p value 0.65).